Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RNTX
stocks logo

RNTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast RNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNTX is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast RNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNTX is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.390
sliders
Low
6.00
Averages
8.00
High
10.00
Current: 1.390
sliders
Low
6.00
Averages
8.00
High
10.00
Brookline
Hold
to
Buy
upgrade
$6
2025-11-03
Reason
Brookline
Price Target
$6
2025-11-03
upgrade
Hold
to
Buy
Reason
Brookline upgraded Rein Therapeutics to Buy from Hold with a $6 price target.
H.C. Wainwright
Brandon Folkes
Buy
initiated
$10
2025-09-22
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$10
2025-09-22
initiated
Buy
Reason
H.C. Wainwright analyst Brandon Folkes initiated coverage of Rein Therapeutics with a Buy rating and $10 price target. The shares can outperform over the next 12 months given the company's "potential best-in-class pipeline," the analyst tells investors in a research note. The firm expects the biggest share catalyst to be the initial data readout of the Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis.
Brookline
Kemp Dolliver
Buy
to
Hold
downgrade
2025-08-19
Reason
Brookline
Kemp Dolliver
Price Target
2025-08-19
downgrade
Buy
to
Hold
Reason
Brookline analyst Kemp Dolliver downgraded Rein Therapeutics to Hold from Buy without a price target. The company's Q2 update was "disappointing" as it is is still waiting for a meeting with the FDA regarding the clinical hold of the Phase 2 RENEW trial, the analyst tells investors in a research note. The firm cites funding concerns and Rein 's lack of progress on the clinical hold for the downgrade.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Rein Therapeutics Inc (RNTX.O) is -1.65, compared to its 5-year average forward P/E of -1.69. For a more detailed relative valuation and DCF analysis to assess Rein Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.69
Current PE
-1.65
Overvalued PE
-0.92
Undervalued PE
-2.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.16
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.37
Undervalued EV/EBITDA
-0.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RNTX News & Events

Events Timeline

(ET)
2025-11-06
08:22:17
Rein Therapeutics Reveals Publication Regarding LTI-03
select
2025-11-03 (ET)
2025-11-03
07:32:23
Rein Therapeutics Obtains FDA Approval to Continue Phase 2 Trial of LTI-03
select
2025-10-09 (ET)
2025-10-09
07:31:57
Rein Secures European Regulatory Clearance to Begin Phase 2 Trial of LTI-03
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-04Benzinga
What’s Behind the Rise in Rein Therapeutics Stock on Monday?

  • Stock Performance: Rein Therapeutics (RNTX) stock rose 16.29% to $1.82, with a trading volume significantly higher than its average.

  • FDA Approval: The FDA lifted the clinical hold on Rein's Phase 2 RENEW trial for LTI-03 in idiopathic pulmonary fibrosis, allowing the study to proceed after addressing all concerns.

  • Trial Details: The trial will resume patient recruitment in late 2025 or early 2026, involving around 20 U.S. sites, and aims to evaluate the safety and efficacy of LTI-03 in up to 120 patients.

  • Future Expectations: Initial topline data from the trial is anticipated in the third quarter of 2026, complementing a broader global study with additional sites in several countries.

[object Object]
Preview
9.0
11-03NASDAQ.COM
Rein Therapeutics Receives FDA Approval to Continue Phase 2 Trial of LTI-03 for IPF Patients

  • FDA Lifts Clinical Hold: Rein Therapeutics announced that the FDA has lifted the full clinical hold on its phase 2 trial for LTI-03, allowing the study to proceed after addressing the agency's concerns.

  • CEO's Statement: Brian Windsor, CEO of Rein Therapeutics, highlighted the FDA's decision as a significant milestone, enabling the company to resume patient enrollment and advance the treatment for idiopathic pulmonary fibrosis (IPF).

  • Patient Recruitment Timeline: Rein plans to resume patient recruitment in late 2025 or early 2026 at around 20 clinical sites across the U.S., complementing its global RENEW study with additional sites in the UK, Germany, Poland, and Australia.

  • Trial Objectives: The trial aims to evaluate the safety, tolerability, and efficacy of LTI-03 in up to 120 patients with IPF, focusing on its potential to slow fibrosis and support lung repair.

[object Object]
Preview
9.0
11-03Newsfilter
Rein Therapeutics Granted FDA Approval to Restart Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis in the U.S.

  • FDA Approval: The FDA has lifted the clinical hold on Rein Therapeutics' Phase 2 trial for LTI-03, allowing the company to resume U.S. patient enrollment expected in late 2025 or early 2026 across 20 clinical sites.

  • LTI-03 Potential: Early data indicates that LTI-03 may not only slow fibrosis in idiopathic pulmonary fibrosis (IPF) patients but also promote lung healing, representing a dual-action approach to treatment.

  • Global Study Expansion: The U.S. enrollment will complement a broader global study that includes approximately 30 additional sites in the UK, Germany, Poland, and Australia, aiming to evaluate the safety and efficacy of LTI-03 in up to 120 patients.

  • Market Need: IPF is a progressive lung disease with limited treatment options, highlighting the urgent need for new therapies, as the global market for fibrosis treatments is projected to exceed $11 billion by 2031.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Rein Therapeutics Inc (RNTX) stock price today?

The current price of RNTX is 1.39 USD — it has increased 0.72 % in the last trading day.

arrow icon

What is Rein Therapeutics Inc (RNTX)'s business?

Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).

arrow icon

What is the price predicton of RNTX Stock?

Wall Street analysts forecast RNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNTX is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Rein Therapeutics Inc (RNTX)'s revenue for the last quarter?

Rein Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Rein Therapeutics Inc (RNTX)'s earnings per share (EPS) for the last quarter?

Rein Therapeutics Inc. EPS for the last quarter amounts to -0.21 USD, decreased -22.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Rein Therapeutics Inc (RNTX)'s fundamentals?

The market is revising No Change the revenue expectations for Rein Therapeutics Inc. (RNTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 4.51%.
arrow icon

How many employees does Rein Therapeutics Inc (RNTX). have?

Rein Therapeutics Inc (RNTX) has 11 emplpoyees as of December 05 2025.

arrow icon

What is Rein Therapeutics Inc (RNTX) market cap?

Today RNTX has the market capitalization of 36.54M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free